A second BCL-2 blocker clears FDA for mantle-cell lymphoma on response alone

The Food and Drug Administration granted accelerated approval on 13 May to Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle-cell lymphoma who have had at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor [s1][s2][s3]. The clearance rests on a single-arm trial in which 52% of 103 patients responded; the drug has not been shown to extend life, and a confirmatory trial must still justify the approval [s2].

Sonrotoclax, made by BeOne Medicines, blocks BCL-2, a protein that lymphoma cells use to evade the self-destruct signals that would otherwise kill them [s2]. It is the second BCL-2 inhibitor to reach the US market; the trial that supported this approval specifically excluded anyone who had already received a drug in that class [s2]. For patients whose disease has outrun a BTK inhibitor — the backbone of modern mantle-cell treatment — the practical question is whether a new mechanism buys durable control.

What the trial showed

Efficacy came from BGB-11417-201, an open-label study with no comparator group [s2]. All 103 evaluable patients had previously received anti-CD20 therapy and a BTK inhibitor; the median patient had already been through three lines of treatment, and the range ran to eight [s2]. Ibrutinib, zanubrutinib and pirtobrutinib were the most common prior BTK drugs, at 53%, 27% and 14% of patients [s2]. Nineteen percent had also received lenalidomide, 17% an autologous stem-cell transplant, and 2% CAR-T therapy [s2] — a heavily pretreated group with few options left. By the simplified mantle-cell prognostic index, 35% were low risk, 36% intermediate and 29% high [s2].

An independent review committee, applying the 2014 Lugano criteria, recorded an overall response rate of 52% (95% confidence interval, 42 to 62) [s2]. Sixteen percent of patients had a complete response and 37% a partial response [s2]. The median time to response was 1.9 months, and the median duration of response was 15.8 months, though the upper bound of that estimate was not reached at a median follow-up of 11.9 months [s2]. Patients took 320 mg once daily after a stepped ramp-up designed to limit tumour lysis syndrome [s2].

What accelerated approval does and does not settle

The approval was granted on the basis of response rate and duration of response — tumours shrinking, and staying shrunk for a while — not on how long patients lived or how long they went before their disease worsened [s1][s2]. Under the accelerated pathway the agency accepts that measurement as a stand-in, on the condition that a confirmatory trial follows; continued approval "may be contingent upon verification and description of clinical benefit," the label states [s2]. This is the same bargain the FDA struck in recent oncology clearances such as the HER2 lung-cancer drug sevabertinib, where a response rate cleared the market and the survival trial reports years later.

A single-arm design cannot tell a reader what response rate the same patients would have shown on another drug, because there is no other group to compare against [s2]. That is the central limit here: 52% is a real number, but it is a number without a control.

The safety ledger

The label carries warnings for tumour lysis syndrome — the rapid breakdown of dying cancer cells that can overwhelm the kidneys — which is why dosing begins with a weeks-long ramp-up rather than the full dose [s2]. That risk is familiar from the BCL-2 class and is the reason treatment is not started at full strength [s2].

For the mantle-cell population, sonrotoclax joins a small set of options after BTK-inhibitor failure, a setting where responses have historically been hard to sustain. Whether this drug changes survival, as opposed to shrinking tumours for a median of just over a year, is precisely what the required confirmatory trial exists to answer [s1][s2]. Until it reports, the honest description is a drug with a real but unvalidated signal — cleared, like a growing share of cancer medicines that reach patients through response-based approvals, on a promise it has yet to keep.

Sources

• [s1] U.S. Food and Drug Administration. NDA 220711 Accelerated Approval Letter — Beqalzi (sonrotoclax) tablets. 13 May 2026.
• [s2] U.S. Food and Drug Administration. Beqalzi (sonrotoclax) tablets — Prescribing Information. 13 May 2026.
• [s3] U.S. Food and Drug Administration. Drugs@FDA: NDA 220711 (Beqalzi) — approval record. 13 May 2026.